WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors : type 1 T-lymphocyte responses are associated with clinical outcome
Source
Journal of hematology and oncology - ISSN 1756-8722-18:1 (2025) p. 1-6
Real-life data of luspatercept in lower-risk myelodysplastic syndromes advocate new research objectives
Source
EJHaem - ISSN 2688-6146-5:5 (2024) p. 1096-1099
Analysis of Wilms' tumor protein 1 specific TCR repertoire in AML patients uncovers higher diversity in patients in remission than in relapsed
Source
Annals of hematology - ISSN 0939-5555- (2024) p.
Designing and combining chimeric antigen receptors for improved cellular immunotherapy of hematological malignancies
Source
Antwerp, University of Antwerp, Faculty of Medicine and Health Sciences, 2024,239 p.
Integration of the PD-L1 inhibitor atezolizumab and WT1/DC vaccination into standard-of-care first-line treatment for patients with epithelioid malignant pleural mesothelioma—Protocol of the Immuno-MESODEC study
Source
PLoS ONE - ISSN 1932-6203-19:7 (2024) p. 1-15